Playback speed
10 seconds
SGO 2024 Insights: "innovaTV 301/ENGOT-cx12/GOG-3057 Study - Efficacy & Safety of Tisotumab Vedotin vs. Investigator's Choice of Chemo in 2L/3L Recurrent/Metastatic Cervical Cancer"
By
Insights from 2024 SGO Annual Meeting
FEATURING
Brian Slomovitz
By
Insights from 2024 SGO Annual Meeting
FEATURING
Brian Slomovitz
312 views
April 12, 2024
Comments 0
Login to view comments.
Click here to Login